Joint statement between Australia and the UK on life sciences and biotechnology cooperation
Australia and the United Kingdom reaffirm their commitment to bilateral cooperation in life sciences and biotechnology.
Meeting in Canberra on 15 September 2026, representatives of both governments agreed to continue cooperation across the life sciences ecosystem, recognising its importance to improving health outcomes, driving innovation-led growth, attracting investment, and creating high-value jobs.
Australia and the United Kingdom share world-class capabilities in health and medical research, clinical development, biotechnology innovation, advanced manufacturing, and commercialisation. Both countries recognise the value of connecting researchers, clinicians, regulators, investors, and industry to translate scientific discoveries into safe and effective products, services and treatments that benefit patients and support economic growth.
Since the inaugural Strategic Innovation Dialogue in London in April 2024, life sciences have remained a specific priority for bilateral innovation cooperation. Australia and the United Kingdom have strengthened engagement across government, research and industry and identified opportunities across the life sciences value chain, from research and clinical validation through to regulation, commercialisation, investment, and market access.
Both countries will advance cooperation in areas including clinical trials, genomics and precision medicine, biotechnology innovation, digital health, advanced therapies, regulatory excellence, and pathways to commercialisation. This cooperation will support more efficient development pathways, stronger partnerships, and greater opportunities for innovative companies in both markets.
Australia and the United Kingdom will continue to work through governments, regulators, research organisations, industry bodies, and innovation partners to translate shared strengths into practical health and economic outcomes.
Specific commitments by participating agencies and organisations are outlined below.
Commitments
Therapeutic Goods Administration (TGA) and the Medicines and Healthcare products Regulatory Agency (MHRA)
The Therapeutic Goods Administration (TGA) and Medicines and Healthcare products Regulatory Agency (MHRA) have a close regulatory relationship, supported by memoranda of understanding that facilitates work-sharing and regulatory information exchange. Both organisations continue to collaborate bilaterally and through the multi-lateral Access Consortium, the International Coalition of Medicines Regulatory Authorities and the International Medical Device Regulators Forum.
Through the Access Consortium, alongside the national regulatory authorities of Canada, Singapore and Switzerland, the TGA and MHRA align regulatory and policy approaches, reduce duplication in regulatory reviews and streamline regulatory processes. The consortium also provides a testing ground for collaborative regulatory approaches that can inform broader international initiatives.
Coordinated reviews through the Access Consortium generate efficiencies for regulators and industry, support timely patient access to safe, effective and high-quality medicines, and create a more attractive market opportunity for global companies. The TGA and MHRA will continue to share experience on novel regulatory approaches and support access to innovative health products.
The agencies also welcomed ongoing cooperation on medical devices regulation, including continuing implementation of the Australia-United Kingdom Mutual Recognition Agreement on conformity assessment for medical devices. Both agencies reaffirmed their commitment to continued collaboration on regulatory approaches that support innovation, reduce unnecessary regulatory burdens, and maintain robust protections for patients and consumers.
Austrade and the UK Department for Business, Innovation, Science and Trade (BIST)
Austrade and the UK Department for Business, Innovation, Science and Trade will promote bilateral trade, investment, innovation, market access, and company connections across shared priorities, including clinical trials, genomics, health data, digital health, biotechnology, medical technology, and advanced therapies.
Austrade and BIST will continue to work with government, industry, research and investment partners to strengthen bilateral commercial and research partnerships, increase opportunities for investment, exports, and business growth, and raise the profile of Australian and UK life sciences capabilities in each other’s markets.
The Australian Clinical Trials Initiative (ACTI) is a national export promotion program delivered under the Australian Government’s Accessing New Markets Initiative to promote Australia as a leading clinical trials destination.
In May 2026, Austrade delivered two ACTI industry seminars at Australia House in London and Milton Park in Oxfordshire, in collaboration with BioUK, One Nucleus and AusBiotech. The seminars brought together pharmaceutical, biotechnology, research, and investment stakeholders to highlight Australia’s clinical trials capabilities, connect Australian and UK organisations and support commercial opportunities for Australian clinical trials organisations. AusTrade will continue to deliver practical support for the sector.
AUScelerate and UK Catapult organisations
Since the inaugural UK-Australia Strategic Innovation Dialogue in 2024, AUScelerate and UK Catapult organisations have supported collaborations with Australian companies, universities and research organisations across cell and gene therapies, radiopharmaceuticals, isotope supply, and advanced molecular imaging.
The Cell and Gene Therapy Catapult has supported an Australian company developing innovative cell therapy production systems to demonstrate its technology and increase its visibility within the UK biotechnology ecosystem. It has also provided health economics and market access analysis to an Australian university research group developing a novel stem cell treatment for heart failure.
The Medicines Discovery Catapult is collaborating with Australian partners through InnovateUK’s Sustainable Medicines Manufacturing Innovation programme to support a secure supply of lead-212 and accelerate the development of targeted alpha therapies.
AUScelerate has supported collaboration between Medicines Discovery Catapult and entX. Isomedica, entX’s nuclear medicine brand, is developing ’Mine to Medicine’ technologies to recover valuable isotopes from low-level radioactive waste streams and supply precursors for nuclear medicine. The collaboration has provided Medicines Discovery Catapult with access to materials for radiotherapy development, supporting research into critical and emerging cancer therapies.
Medicines Discovery Catapult is also exploring cooperation with Australian academic partners in advanced molecular imaging, including access to facilities, and linking UK and Australian total-body positron emission tomography imaging networks. These activities support further cooperation in radiopharmaceutical development, isotope supply, and preclinical translation.
AUScelerate and UK partners will continue to strengthen these collaborations and provide support and certainty for collaborative development projects. Through the Australian Antimicrobial Resistance Network, AUScelerate also maintains links with the UK-based Wellcome Trust and works with the National Health Service to support clinician entrepreneurship in Australia.
AusBiotech and the UK BioIndustry Association (BIA)
AusBiotech, and the UK BIA supports members to advance biotechnology, medical technology, and health technology innovation. They work closely with the Medicines Discovery Catapult, and the British Consulate-General to strengthen industry connections, regulatory alignment, trade and investment, and multijurisdictional research and development.
In 2025, AusBiotech convened four 4 bilateral forums with UK partners:
- Forums held in March and May explored opportunities for stronger industry partnerships, including collaboration with Medicines Discovery Catapult.
- On 16 June 2025, AusBiotech and the BIA convened the Australia-UK Bilateral Biotech Roundtable at the BIO International Convention in Boston. The organisations signed a memorandum of understanding to strengthen policy alignment and collaboration between the Australian and UK biotechnology industries.
- In October 2025, AusBiotech, Medicines Discovery Catapult and the British Trade Consul brought Australian and UK stakeholders together at the AusBiotech International Conference to identify further areas for cooperation. AusBiotech also commissioned a regulatory handbook to support Australian biotechnology companies seeking to operate and develop partnerships in the United Kingdom.
AusBiotech’s leadership met the United Kingdom’s Trade Envoy, the Rt Hon. the Lord Spellar, in March 2025 to discuss bilateral life sciences trade and investment. The BIA has also supported Australian companies to establish and expand their presence in the UK biotechnology ecosystem.
AusBiotech and the BIA will continue to strengthen bilateral industry connections through policy engagement, information sharing, business and investor networks, and support for companies seeking cross-border partnerships and access to each other’s markets.
Indicative participating organisations
The following organisations remain committed to driving life sciences cooperation, innovation and commercialisation across Australia and the UK:
Australia:
- TGA
- Austrade
- AUScelerate
- AusBiotech
- National Health and Medical Research Council (NHMRC) / Medical Research Future Fund (MRFF)
- CSIRO
- Omico
- Brandon Capital and other relevant investors
- relevant contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs).
United Kingdom:
- MHRA
- OLS
- Cell and Gene Therapy Catapult
- Medicines Discovery Catapult
- Innovate UK
- UK Research and Innovation (UKRI)
- BIA
- National Institute for Health and Care Research (NIHCR)
- relevant contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs).